Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-039/12
A61K-039/00
A61K-047/00
출원번호
US-0123887
(2009-10-09)
등록번호
US-8906381
(2014-12-09)
국제출원번호
PCT/US2009/060233
(2009-10-09)
§371/§102 date
20111118
(20111118)
국제공개번호
WO2010/042863
(2010-04-15)
발명자
/ 주소
Iannacone, Matteo
Alexis, Frank
Basto, Pamela
Moseman, Elliott Ashley
Shi, Jinjun
Langer, Robert S.
Farokhzad, Omid C.
von Andrian, Ulrich
Tonti, Elena
출원인 / 주소
Massachusetts Institute of Technology
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
6인용 특허 :
191
초록▼
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In s
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising such nanocarriers. The present invention provides methods of designing, manufacturing, and using such nanocarriers and pharmaceutical compositions thereof.
대표청구항▼
1. A composition comprising: (1) synthetic nanocarriers comprising: (a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding,(b) a B-cell antigen, and(c) immunostimulatory a
1. A composition comprising: (1) synthetic nanocarriers comprising: (a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding,(b) a B-cell antigen, and(c) immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and(2) a pharmaceutically acceptable excipient. 2. The composition of claim 1, wherein the plurality of moieties forming the immunofeature surface are present in a density equal to or greater than the density required to obtain at least 1% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay, provided that, in the APC binding assay, the half maximal binding density for the plurality of moieties forming the immunofeature surface is at least twice the half maximal binding density for the MAb. 3. The composition of claim 2, wherein the plurality of moieties forming the immunofeature surface are present in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in the APC binding assay. 4. The composition of claim 2, wherein the half maximal binding density for the plurality of moieties forming the immunofeature surface is at least four times the half maximal binding density for the MAb. 5. The composition of claim 2, wherein the APC binding assay comprises: (a) preparing a series of substrates having coatings of an functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to a dendritic cell (DC) or subcapsular sinus macrophage surface receptors;(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophages for a predetermined period of time;(c) removing non-adhered APCs from the series of substrates, and fixing the adhered APCs to the series of substrates;(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;(e) plotting the result from (d) against the coating density of the functional moiety;(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum. 6. The composition of claim 2, wherein the MAb is anti-CD1c (BDCA-1) Clone AD5-8E7 or rat anti-mouse CD169 clone 3D6.112. 7. The composition of claim 1, wherein the composition stimulates the production of anti-B-cell antigen IgG antibodies when administered to a human. 8. The composition of claim 1, wherein the immunostimulatory agent is selected from the group consisting of an interleukin, an interferon, a cytokine, and an adjuvant. 9. The composition of claim 1, wherein the B-cell antigen is selected from the group consisting of proteins, peptides, small molecules, and carbohydrates. 10. A method comprising administering to a subject an initial dose of a composition comprising: (1) synthetic nanocarriers comprising: (a) an immunofeature surface formed of an array of binding moieties, the array having high avidity and low affinity binding to antigen presenting cells as compared to antibody binding,(b) a B-cell antigen, and(c) an immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and(2) a pharmaceutically acceptable excipient;wherein the composition is in an amount effective to induce the production of anti-B-cell antigen IgG antibodies such that the peak serum concentration of anti-B-cell antigen IgG antibodies is raised to greater than 100 ng/ml in the subject after the administration. 11. The method of claim 10, further comprising administering at least one additional dose to the subject at a time after the initial dose. 12. The method of claim 11, wherein the time after the initial dose is between 1 day and 1 year. 13. The composition of claim 1 wherein the at least one surface of the synthetic nanocarriers comprises a plurality of moieties in an amount effective to provide a humoral response to the moieties; and wherein the moieties are present in an amount effective to provide avidity-based binding to mammalian antigen presenting cells. 14. The composition of claim 13, wherein the diameter of the nanocarriers is greater than 100 nm. 15. The composition of claim 13, wherein the pharmaceutically acceptable excipient is selected from solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants. 16. The composition of claim 13, wherein the composition targets a subcapsular sinus macrophage. 17. The composition of claim 13, wherein the composition targets a dendritic cell. 18. The composition of claim 13, wherein the composition does not substantially activate complement. 19. The composition of claim 13, wherein the composition further comprises a high affinity targeting moiety. 20. The composition of claim 13, wherein the composition further comprises an immunomodulatory agent. 21. A method for stimulating an immune response comprising administering a composition comprising: (1) synthetic nanocarriers comprising: (a) an immunofeature surface formed of an array of binding moieties, the array providing for high avidity and low affinity binding to antigen presenting cells as compared to antibody binding,(b) a B-cell antigen, and(c) an immunostimulatory agent, wherein the nanocarriers comprise substantially no T-helper antigen; and(2) a pharmaceutically acceptable excipientwherein the nanocarriers comprises a plurality of moieties in an amount effective to provide a humoral response to the moieties.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (191)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Bomberger David C. ; Catz Paul G. ; Smedley Mark I. ; Stearns Paul C., Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Speaker Tully J. (Philadelphia PA) Sultzbaugh Kenneth J. (Philadelphia PA), Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Setterstrom, Jean A.; Tice, Thomas R.; Jacob, Elliot; Reid, Robert H.; van Hamont, John; Boedecker, Edgar C.; Jeyanthi, Ramassubbu; Friden, Phil; Roberts, F. Donald; McQueen, Charles E.; Bhattacharje, Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.